Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has upgraded Third Harmonic Bio (NASDAQ:THRD) from Equal-Weight to Overweight and raised the price target from $12 to $20.
August 09, 2024 | 9:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has upgraded Third Harmonic Bio (NASDAQ:THRD) from Equal-Weight to Overweight and raised the price target from $12 to $20.
The upgrade from Equal-Weight to Overweight and the significant increase in the price target from $12 to $20 by a reputable firm like Morgan Stanley is likely to positively impact the stock price of Third Harmonic Bio in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100